Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avon products pty limited - picaridin - aerosol - picaridin piperidine active 97.0 g/kg - household insecticide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avon products pty limited - picaridin - liquid - picaridin piperidine active 90.0 g/l - household insecticide

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

avon cosmetics (malaysia) sendirian berhad - rosa rugosa; vitis vinifera -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

avon cosmetics (malaysia) sendirian berhad - collagen peptide; taurine; sodium ascorbate; fructooligosaccharides -

United States - English - NLM (National Library of Medicine)

biogen inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 30 ug in 0.5 ml - avonex is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. avonex is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation [see warnings and precautions (5.3)] . the formerly available lyophilized vial formulation of avonex is contraindicated in patients with a history of hypersensitivity to albumin (human). risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta products during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent (see data). in a study in pregnant monkeys, administration of interfer

United States - English - NLM (National Library of Medicine)

mitsubishi tanabe pharma america, inc. - edaravone (unii: s798v6yjrp) (edaravone - unii:s798v6yjrp) - edaravone 30 mg in 100 ml - radicava and radicava ors are indicated for the treatment of amyotrophic lateral sclerosis (als). radicava and radicava ors are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in this product. hypersensitivity reactions and anaphylactic reactions have occurred [see warnings and precautions (5.1 , 5.2 )]. risk summary there are no adequate data on the developmental risk associated with the use of radicava or radicava ors in pregnant women. in animal studies, administration of edaravone to pregnant rats and rabbits resulted in adverse developmental effects (increased mortality, decreased growth, delayed sexual development, and altered behavior) at clinically relevant doses. most of these effects occurred at doses that were also associated with maternal toxicity (see animal data ) . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk for major birth defects and miscarriage in patients with als is unknown. data animal data in rats, intravenous administration of edaravone (0, 3, 30, or 300 mg/kg/day) throughout the period of organogenesis resulted in reduced fetal weight at all doses. in dams allowed to deliver naturally, offspring weight was reduced at the highest dose tested. maternal toxicity was also observed at the highest dose tested. there were no adverse effects on reproductive function in the offspring. a no-effect dose for embryofetal developmental toxicity was not identified; the low dose is less than the recommended human dose of 60 mg for radicava on a body surface area (mg/m2 ) basis. in rabbits, intravenous administration of edaravone (0, 3, 20, or 100 mg/kg/day) throughout the period of organogenesis resulted in embryofetal death at the highest dose tested, which was associated with maternal toxicity. the higher no-effect dose for embryofetal developmental toxicity is approximately 6 times the recommended human dose (rhd) for radicava on a body surface area (mg/m2 ) basis. the effects on offspring of edaravone (0, 3, 20, or 200 mg/kg/day), administered by intravenous injection to rats from gd 17 throughout lactation, were assessed in two studies. in the first study, offspring mortality was observed at the high dose and increased activity was observed at the mid and high doses. in the second study, there was an increase in stillbirths, offspring mortality, and delayed physical development (vaginal opening) at the highest dose tested. reproduction function in offspring was not affected in either study. maternal toxicity was evident in both studies at all but the lowest dose tested. the no-effect dose for developmental toxicity (3 mg/kg/day) is less than the rhd on a mg/m2 basis. reproductive and developmental toxicology studies of edaravone using the oral route have not been conducted risk summary there are no data on the presence of edaravone in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. edaravone and its metabolites are excreted in the milk of lactating rats. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for radicava and radicava ors and any potential adverse effects on the breastfed infant from radicava and radicava ors or from the underlying maternal condition. safety and effectiveness of radicava or radicava ors in pediatric patients have not been established of the 184 patients with als who received radicava in 3 placebo-controlled clinical trials, a total of 53 patients were 65 years of age and older, including 2 patients 75 years of age and older. no overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Australia - English - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - interferon beta-1a, quantity: 60 microgram/ml - injection, solution - excipient ingredients: arginine hydrochloride; polysorbate 20; sodium acetate; water for injections; glacial acetic acid - avonex is indicated for the treatment of patients with relapsing forms of multiple sclerosis (ms). avonex is indicated in patients who have experienced a single demyelinating event and are at risk of developing clinically definite ms based on the presence of brain mri abnormalities characteristic of ms. avonex 60 mcg is indicated for the treatment of secondary progressive ms in patients in whom relapse is still a feature of disease. avonex 60 mcg should not be initiated in patients with secondary progressive ms who have not experienced relapse in the previous 12 months.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - edaravone, quantity: 30 mg - injection, concentrated - excipient ingredients: edaravone; sodium bisulfite; sodium chloride; sodium hydroxide; cysteine hydrochloride monohydrate; phosphoric acid; water for injections - radicava is indicated in adults with a diagnosis of amyotrophic lateral sclerosis who are independent in activities of daily living with normal respiratory function and where treatment is initiated within two years of disease onset.,efficacy has not been demonstrated in patients outside of this defined population.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avon products pty limited - ethyl butylacetylaminopropionate - household insecticide - pest control - personal use - black fly | mosquito | mosquito - aedes spp. | mosquito - culex spp. | sand fly (biting midge) | tick | adult mosquitoes

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avon skin-so-soft - citronella oil(0.865g/l) - lotion - insect repellent - pest control - personal use - mosquito | adult mosquitoes